The Association of Coagulation Indicators and Coagulant Agents With 30-Day Mortality of Critical Diabetics.


Journal

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
ISSN: 1938-2723
Titre abrégé: Clin Appl Thromb Hemost
Pays: United States
ID NLM: 9508125

Informations de publication

Date de publication:
Historique:
entrez: 22 7 2021
pubmed: 23 7 2021
medline: 1 12 2021
Statut: ppublish

Résumé

Diabetes, regarded as a global health concerned disease, was focused by the World Health Organization (WHO). Patients with diabetes may have a hypercoagulable and hypo-fibrinolysis state. There is lots of research about cardiovascular effects on diabetes patients, but less about the coagulation system. This study is designed to investigate the relationship between coagulation indicators and 30-day mortality of critical diabetes patients. In this retrospective, single-center study, we included adult patients diagnosed with diabetes. Data, including demographic, complication, laboratory tests, scoring system, and anticoagulant treatment, were extracted from Medical Information Mart for Intensive Care (MIMIC-III). The receiver operating characteristic (ROC) curve and Kaplan-Meier curve were applied to predict the association of mortality and coagulation indicators. Cox hazard regression model and subgroup analysis were used to analyze the risk factors associated with 30-day mortality. A total of 4026 patients with diabetes mellitus were included in our study, of whom 3312 survived after admitted to the hospital and 714 died. Cox hazard regression showed anticoagulant therapy might decrease the risk of 30-day mortality after adjusted. In age <70 subgroup analysis, we found that patients with PTT <26.8 s or lightly increased PT may increase odds of 30-day hospital death (HR, 95%CI, 2.044 (1.376, 3.034), 1.562 (1.042, 2.343)). When age >70, lightly increased PTT may reduce the risk of mortality, but PT >16.3 s, a high level of hypo-coagulation state, increase risk of mortality (HR, 95%CI, 0.756 (0.574, 0.996), 1.756 (1.129, 2.729)). Critical diabetes patients may benefit from anticoagulant agents. The abnormal coagulant function is related to the risk of 30-day mortality.

Identifiants

pubmed: 34291673
doi: 10.1177/10760296211026385
pmc: PMC8312190
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

10760296211026385

Références

J Diabetes. 2018 May;10(5):353-356
pubmed: 29345068
Med Princ Pract. 2005 Jan-Feb;14(1):22-30
pubmed: 15608477
Pathophysiol Haemost Thromb. 2008;36(3-4):195-203
pubmed: 19176992
Lancet Rheumatol. 2020 Jul;2(7):e437-e445
pubmed: 32835247
Vascular. 2019 Jun;27(3):299-311
pubmed: 30539687
Hematol Oncol Clin North Am. 2016 Oct;30(5):1099-114
pubmed: 27637310
Sci Data. 2016 May 24;3:160035
pubmed: 27219127
Mayo Clin Proc. 2007 Jul;82(7):864-73
pubmed: 17605969
J Diabetes Complications. 2016 May-Jun;30(4):738-45
pubmed: 26781070
Blood Rev. 2021 May;47:100761
pubmed: 33067035
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Diabetes Complications. 2001 Jan-Feb;15(1):44-54
pubmed: 11259926
J Thromb Haemost. 2007 Apr;5(4):729-37
pubmed: 17408406
Diabetes Care. 2021 Jan;44(Suppl 1):S15-S33
pubmed: 33298413
Blood Rev. 1988 Jun;2(2):88-94
pubmed: 3042061
Crit Care. 2008;12(2):R41
pubmed: 18358078
J R Coll Physicians Edinb. 2014;44(1):42-5
pubmed: 24995447
Trends Cardiovasc Med. 2016 May;26(4):364-73
pubmed: 26654259
Oncotarget. 2016 Jul 19;7(29):44879-44905
pubmed: 27270647
Clin Chim Acta. 2020 May;504:109-118
pubmed: 32044332
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620950837
pubmed: 32862673
Inflamm Res. 2018 May;67(5):391-405
pubmed: 29372262
J Clin Pathol. 2019 Apr;72(4):325-328
pubmed: 30593460
Nihon Gan Chiryo Gakkai Shi. 1989 Mar 20;24(3):579-84
pubmed: 2671204
Eur J Prev Cardiol. 2019 Dec;26(2_suppl):7-14
pubmed: 31766915

Auteurs

Yingxin Huang (Y)

Department of Nephrology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.

Zhihua Zhong (Z)

College of Information Science and Technology, Jinan University, Guangzhou, Guangdong, China.

Fanna Liu (F)

Department of Nephrology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH